Moderna shares rose more than 2% in early trading.
- A study examining the immune response of Moderna's COVID-19 vaccine to Pfizer /BioNTech's found that the former created more than twice as many antibodies as the latter.
- The study, published in theJournal of the American Medical Association, examined 2,499 health care workers in Belgium inoculated with one of the two vaccines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments